Board Committees

Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.

Mr. Coffey is a registered company auditor and audits a number of large private companies, as well as a number of not-for-profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of two private ancillary funds (PAFs).

Mr. Coffey was appointed as a non-executive director to the Company in November 2012 and is considered to be an independent director. He is Chair of the Audit, Risk, and Governance Committee and a member of the Remuneration and Nomination Committee.

Robert Apple has more than 25 years of senior leadership experience in the pharmaceutical industry, including 16 years with Antares Pharma, Inc. as Senior Vice President, Chief Financial Officer, and Corporate Secretary, before going on to become President and Chief Executive Officer from 2016 until its acquisition by Halozyme Therapeutics in 2022. Mr. Apple also served on the Board of Directors at Antares from 2016 until May 2022. He previously served on the Board of Directors of InKine Pharmaceutical, PaxMedica Inc., and Kerathin Inc.

Prior to joining Antares, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical. He also held prior roles at Genaera Corporation, Liberty Technologies, and Arthur Andersen & Company.

Mr. Apple holds a Bachelor of Administration degree in accounting from Temple University, Philadelphia.

Mr. Apple was appointed as a non-executive director of the company in January 2024 and Chairman on April 1, 2026. He is a member of both the Audit, Risk, and Governance Committee and the Remuneration and Nomination Committee. 

Ebru Davidson is a director and senior executive with more than 18 years of experience supporting public and private companies through growth, capital formation, and strategic corporate activity. Her background spans corporate law, equity capital markets, M&A, complex transactions, governance, and organizational leadership and she has a strong track record guiding and advising companies operating in highly regulated sectors.

Ms. Davidson currently serves as Interim CEO and Managing Director of QBiotics Group Limited, a public unlisted company developing and commercializing oncology and wound healing drugs. Prior to joining QBiotics in 2021, she was a Partner in the Equity Capital Markets practice with Thomsons, a major Australian law firm.

Ms. Davidson holds a Bachelor of Science from the University of Melbourne and a Juris Doctor (Honors) from Bond University. She is an Associate Member of the Governance Institute of Australia, having completed a Graduate Diploma of Applied Corporate Governance, and is a graduate of the Australian Institute of Company Directors. She is also Non-Executive Director with the Centre for Eye Research Australia.

Appointed as a Non-Executive Director in June 2023, Ms. Davidson is considered an independent director. She is Chair of the Remuneration and Nomination Committee and a member of the Audit, Risk, and Governance Committee. 

Ebru Davidson is a director and senior executive with more than 18 years of experience supporting public and private companies through growth, capital formation, and strategic corporate activity. Her background spans corporate law, equity capital markets, M&A, complex transactions, governance, and organizational leadership and she has a strong track record guiding and advising companies operating in highly regulated sectors.

Ms. Davidson currently serves as Interim CEO and Managing Director of QBiotics Group Limited, a public unlisted company developing and commercializing oncology and wound healing drugs. Prior to joining QBiotics in 2021, she was a Partner in the Equity Capital Markets practice with Thomsons, a major Australian law firm.

Ms. Davidson holds a Bachelor of Science from the University of Melbourne and a Juris Doctor (Honors) from Bond University. She is an Associate Member of the Governance Institute of Australia, having completed a Graduate Diploma of Applied Corporate Governance, and is a graduate of the Australian Institute of Company Directors. She is also Non-Executive Director with the Centre for Eye Research Australia.

Appointed as a Non-Executive Director in June 2023, Ms. Davidson is considered an independent director. She is Chair of the Remuneration and Nomination Committee and a member of the Audit, Risk, and Governance Committee. 

Steven Coffey is a Chartered Accountant, having spent his career in public practice since graduating from NSW University in 1983. He has been a partner in the chartered accounting firm Watkins Coffey Martin since 1993.

Mr. Coffey is a registered company auditor and audits a number of large private companies, as well as a number of not-for-profit entities. He has previously served on the board of an Australian listed public company and is currently a board member of two private ancillary funds (PAFs).

Mr. Coffey was appointed as a non-executive director to the Company in November 2012 and is considered to be an independent director. He is Chair of the Audit, Risk, and Governance Committee and a member of the Remuneration and Nomination Committee.

Robert Apple has more than 25 years of senior leadership experience in the pharmaceutical industry, including 16 years with Antares Pharma, Inc. as Senior Vice President, Chief Financial Officer, and Corporate Secretary, before going on to become President and Chief Executive Officer from 2016 until its acquisition by Halozyme Therapeutics in 2022. Mr. Apple also served on the Board of Directors at Antares from 2016 until May 2022. He previously served on the Board of Directors of InKine Pharmaceutical, PaxMedica Inc., and Kerathin Inc.

Prior to joining Antares, Mr. Apple served as Chief Operating and Financial Officer at InKine Pharmaceutical. He also held prior roles at Genaera Corporation, Liberty Technologies, and Arthur Andersen & Company.

Mr. Apple holds a Bachelor of Administration degree in accounting from Temple University, Philadelphia.

Mr. Apple was appointed as a non-executive director of the company in January 2024 and Chairman on April 1, 2026. He is a member of both the Audit, Risk, and Governance Committee and the Remuneration and Nomination Committee.